REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study

(2015) James S. Ferriss et al.   GYNECOLOGIC ONCOLOGY

Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial

(2015) Hui Zhao et al.   MEDICAL ONCOLOGY

Development of the Measure of Ovarian Symptoms and Treatment Concerns

(2014) Madeleine T. King et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

(2012) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions

(2010) Dejan Ignjatovic et al.   AMERICAN JOURNAL OF SURGERY

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

(2009) John P. Diaz et al.   GYNECOLOGIC ONCOLOGY

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

(2009) Filippo Bellati et al.   INVESTIGATIONAL NEW DRUGS

Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?

(2009) S. Kobold et al.   ONCOLOGIST

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

(2008) Chad A. Hamilton et al.   GYNECOLOGIC ONCOLOGY